Cardiome Pharma (CRME) Misses Q2 EPS by 9c

Cardiome Pharma (NASDAQ: CRME) reported Q2 EPS of ($0.26), $0.09 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $6.96 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c